Date: 2015-02-03
Type of information: Collaboration agreement
Compound: multiplexing technology platform for protein biomarker detection, ophthalmic diagnostic tools
Company: Ayoxxa (Germany) Singapore Eye Research Institute (Singapore)
Therapeutic area: Ophtalmological diseases - Diagnostic
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On February 3, 2015, Ayoxxa, an international biotech company with headquarters in Cologne, has signed an agreement with the Singapore Eye Research Institute (SERI), one of the leading international eye research institutes. The partners will work together on validating the company’s multiplexing technology platform for protein biomarker detection, as part of an expanded collaboration for developing ophthalmic diagnostic tools. Research teams led by Dr. Dieter Trau, Associate Professor at the Department of Biomedical Engineering of the National University of Singapore and Co-founder of AYOXXA, and Prof. Wong Tien Yin, one of world’s top eye researchers and Medical Director at the Singapore National Eye Centre (SNEC), will closely work together during this pilot study. Cytokines and growth factors are known to play a significant role in pathogenesis of angiogenic retinal diseases (ARDs) including age-related macular degeneration (AMD). Sensitive and reliable biomarker assays allow diagnosis and therapy monitoring. Samples need to be taken directly from the vitreous and aqueous compartments of patients’ eyes. The limitations of currently used biomarker evaluation include the demand for relatively large sample volumes, which in some patients, may be difficult to obtain without having to undergo a vitrectomy during surgery. Additionally, established tests are also time-consuming and expensive. As part of this pilot study, cytokine and growth factor concentrations in vitreous and aqueous patient samples will be determined using the Ayoxxa human cytokine bioassays and compared with standard methods. Furthermore, the Ayoxxa protein multiplexing technology will be challenged for reliability using very small sample quantities. The technology might offer a fast, sensitive, reliable and economic testing system for AMD and other ophthalmic diseases, as well as to enable therapy monitoring for the benefit of both, patients and clinicians.
Financial terms:
Latest news:
